Treatment of Somatostatinoma When Liver Metastases Are Present
Somatostatinoma is a rare neuroendocrine tumor that frequently presents at an advanced stage. When liver metastases are identified, curative resection is often no longer feasible, shifting the clinical goal toward reducing overall tumor burden and managing hepatic disease through palliative interventions.
Clinical Situation
In the metastatic setting, liver involvement complicates surgical planning. Because many of these tumors grow slowly, aggressive local management of hepatic metastases remains a meaningful option for appropriate candidates. The approach is tailored to the extent and distribution of liver disease and the patient's overall condition.
Treatment Approach
Management involves palliative cytoreductive (debulking) strategies, including surgical and image-guided interventional options targeting liver metastases. Several modalities — both surgical and catheter-based — may be considered depending on the clinical picture.
The specific selection, sequencing, and eligibility criteria for these approaches are detailed in the full protocol.
References
- However, metastases often preclude curative resection, and palliative debulking can be considered to relieve symptoms.
- The symptoms of metastatic functional pancreatic neuroendocrine tumors (NETs) may be ameliorated by the reduction of overall tumor burden through surgical debulking.
- Because of the slow growth rate of many NETs, liver metastases are often resected when technically feasible.
- Cytoreductive surgery, with or without radiofrequency ablation or cryoablation, has been used to palliate symptoms.
- Alternative approaches to the management of liver metastases have been reported, including Gelfoam embolization or transarterial chemoembolization, radioembolization with radioactive microspheres, radiofrequency ablation, cryoablation, and percutaneous alcohol ablation.
View source ↗